SUTRO BIOPHARMA, INC. (STRO)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, SUTRO BIOPHARMA, INC. reported revenue of $102.48M, up 65.2% from the prior year. The company ran a net loss, with a net margin of -186.5%. It held $173.83M in total assets against $306.28M in total liabilities.
Key ratios (FY2025)
-154.5%
Operating margin
-186.5%
Net margin
+65.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102.48M | $62.04M | $153.73M | $67.77M | $61.88M | $42.72M | $42.74M | $38.42M | $51.74M | — |
| Operating Income | -$158.37M | -$238.45M | -$89.28M | -$128.94M | -$98.52M | -$71.06M | -$55.47M | -$37.22M | -$19.27M | $1.36M |
| Net Income | -$191.09M | -$227.46M | -$106.79M | -$119.20M | -$105.54M | -$32.13M | -$119.20M | -$35.32M | -$19.69M | $1.70M |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | — | — | — | — |
| Total Assets | $173.83M | $387.21M | $470.74M | $406.94M | $341.41M | $394.11M | $156.37M | $223.14M | $40.77M | — |
| Total Liabilities | $306.28M | $342.61M | $321.09M | $189.90M | $88.84M | $62.06M | $58.58M | $91.60M | $47.27M | — |
| Shareholders' Equity | -$132.45M | $44.60M | $149.65M | $217.05M | $252.56M | $332.05M | $97.79M | $131.54M | -$109.00M | -$90.90M |
| Cash & Equivalents | $58.13M | $190.30M | $69.27M | $47.25M | $30.41M | $206.15M | $4.96M | $125.30M | $22.02M | $11.59M |
| Operating Cash Flow | -$177.23M | -$191.54M | -$111.62M | $3.55M | -$81.68M | -$67.80M | -$65.02M | $12.68M | -$37.07M | -$13.15M |
| Capital Expenditures | — | — | — | — | — | — | — | $1.56M | $3.32M | $4.39M |
| Shares Outstanding | 8.58M | 8.31M | 61.01M | 57.50M | 46.33M | 45.75M | 23.10M | 22.85M | 465.3K | — |